This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Christine Brennan
Partner at MRL Ventures Fund


Christine has over 15 years in the life-science industry including business development, corporate strategy and venture investing.  She is currently Partner at MRL Ventures Fund (MRLV). She was previously on the board of Altimmune (NASDAQ:ALT) and an observer on the boards on a number of companies including ROX Medical, Innocrin Pharmaceuticals, Quartet Medicine and Viamet Pharmaceuticals. She is currently responsible for MRLV’s investments in Entrada Therapeutics, Alector (NASDAQ:ALEC) and Translate Bio (NASDAQ:TBIO).

Prior to MRLV, she was Principal at the Novartis Venture Fund from 2013-2017 and Chief Business Officer at Vitae Pharmaceuticals from 2010-2013.  She also held positions in business development and marketing at small biopharmaceutical and large pharmaceutical companies.  Christine received her Ph.D. in neuroscience from Dartmouth Medical School and did post-doctoral research in developmental neurobiology at the National Institutes of Health.